Cormedix Inc. — FY2021 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter report. Figures below are compared with FY2020 unless noted. Amounts are in U.S. dollars.
Business context
CorMedix is a development-stage biopharmaceutical company focused on preventing and treating infectious and inflammatory diseases. Its lead candidate, DefenCath (taurolidine and heparin), is intended to reduce catheter-related bloodstream infections in chronic hemodialysis patients. The related product Neutrolin is CE-marked as a medical device and available in certain non-U.S. markets; sales remain limited.
Key financial metrics
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $0.191 million | $0.239 million |
| Gross profit / gross margin | $0.042 million / approximately 22.0% | $0.034 million / approximately 14.4% |
| Research and development expense | $13.133 million | $13.377 million |
| Selling, general and administrative expense | $16.347 million | $13.878 million |
| Operating loss | $29.438 million | $27.221 million |
| Net loss | $28.210 million | $22.028 million |
| Net loss per share, basic and diluted | $0.75 | $0.77 |
| Net cash used in operating activities | $21.155 million | $21.968 million |
At year-end, cash and cash equivalents were $53.317 million and short-term investments were $12.149 million; together they totaled $65.466 million, excluding restricted cash. Total assets were $68.946 million, total liabilities $6.148 million, and stockholders’ equity $62.798 million. Liabilities included $0.924 million of operating lease obligations; the balance sheet reports no conventional borrowings. The company reported an accumulated deficit of $245.659 million.
Financing provided $41.758 million of net cash, primarily from $41.456 million of ATM share sales. Investing activities used $9.135 million, including purchases of short-term investments and equipment. The company issued 3.738 million shares through its ATM program during 2021.
Material changes versus FY2020
- Revenue declined 20% to $0.191 million, reflecting lower sales in the Middle East and Europe. Gross margin increased to approximately 22.0% from 14.4%, but the business remains far from operating profitability.
- Net loss widened 28%, mainly as SG&A rose 18% amid higher stock-based compensation and personnel costs. R&D expense decreased slightly, reflecting lower pre-approval manufacturing and completed-trial costs, partly offset by NDA resubmission consulting and other expenses.
- Operating cash use decreased by $0.813 million. The company raised substantially more capital through its ATM program, while year-end cash and short-term investments rose to $65.466 million from $46.350 million.
- Stock-based compensation expense increased to $5.043 million from $2.500 million. The auditor identified stock-based compensation valuation and performance conditions as a critical audit matter.
Outlook, risks and unusual items
- DefenCath regulatory status: The FDA issued a Complete Response Letter in March 2021 citing manufacturing-facility deficiencies and requiring a manual extraction study. The company reported that the study was completed and resubmitted the NDA on February 28, 2022. After year-end, on March 28, 2022, the FDA accepted the resubmission as a complete Class 2 response with a six-month review cycle. The FDA had not requested additional clinical data or identified efficacy or safety deficiencies in LOCK-IT-100; approval remains uncertain and may depend on verification of manufacturing corrective actions and possible inspection.
- Clinical evidence and potential scope: LOCK-IT-100 enrolled 795 subjects and showed a reported 71% reduction in CRBSI risk versus heparin (p=0.0006). Draft labeling discussed with FDA limited initial use to chronic hemodialysis patients with kidney failure and a central venous catheter. Additional indications are prospective, not approved.
- Liquidity and funding: Management stated that year-end cash and investments should fund operations through at least the first half of 2023, including NDA resubmission costs and initial launch preparation. Further funding may be needed for commercialization and development; additional equity could dilute shareholders. At December 31, 2021, $50 million remained under an ATM program and $150 million under a shelf registration. In Q1 2022, the company raised approximately $3.0 million net through ATM sales.
- Contingencies and operational risks: The company faces securities class-action litigation alleging misstatements concerning the DefenCath NDA and a related derivative action; it intends to contest the claims. In Germany, the European patent underlying a separate infringement dispute was revoked and is under appeal; an unfair-competition appeal was withdrawn, with approximately $41,000 plus interest in costs payable. CorMedix relies on third-party manufacturers, and an inspection backlog related to COVID-19 could delay FDA review.
- Management and governance: CEO Khoso Baluch retired in October 2021, and Matthew David became interim CEO in addition to CFO. After year-end, Joseph Todisco was appointed CEO, with commencement no later than May 16, 2022. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor expressed an unqualified opinion on the financial statements but was not engaged to audit internal controls.
- Tax benefit: The FY2021 tax benefit was $1.250 million, compared with $5.169 million in FY2020, principally associated with sales of New Jersey net operating loss tax benefits. The company maintained a full valuation allowance against deferred tax assets.
Important facts for investors to verify
- FDA review milestones, any inspection or further manufacturing requests, and whether the NDA is approved on the stated review schedule.
- Cash burn, remaining liquidity, ATM usage and potential dilution, especially if approval or launch costs exceed current plans.
- Commercial readiness, reimbursement eligibility and actual demand for DefenCath if approved; current Neutrolin revenue is very small.
- Progress and potential financial exposure in the securities and derivative lawsuits, and the status of the European patent appeal.
- Changes in executive leadership, stock-based compensation and share count, as well as the assumptions supporting management’s runway estimate through the first half of 2023.